Hepatectomy After Conversion Therapy Using Tyrosine Kinase Inhibitors Plus Anti-PD-1 Antibody Therapy for Patients with Unresectable Hepatocellular Carcinoma

BACKGROUND: Combined treatment with tyrosine kinase inhibitors (TKI) plus anti-PD-1 antibodies showed high anti-tumor efficacy and made conversion resection possible for patients with unresectable hepatocellular carcinoma (HCC). However, long-term survival has not been reported. METHODS: A cohort of...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhu, Xiao-Dong, Huang, Cheng, Shen, Ying-Hao, Xu, Bin, Ge, Ning-Ling, Ji, Yuan, Qu, Xu-Dong, Chen, Lingli, Chen, Yi, Li, Mei-Ling, Zhu, Jin-Jin, Tang, Zhao-You, Zhou, Jian, Fan, Jia, Sun, Hui-Chuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Hepatobiliary Tumors
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10085942/
https://www.ncbi.nlm.nih.gov/pubmed/36178565
http://dx.doi.org/10.1245/s10434-022-12530-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10085942/
https://www.ncbi.nlm.nih.gov/pubmed/36178565
http://dx.doi.org/10.1245/s10434-022-12530-z

Ejemplares similares